| Company Name: |
MedChemexpress LLC
|
| Tel: |
021-58955995 |
| Email: |
sales@medchemexpress.cn |
| Products Intro: |
Product Name:Imiquimod (maleate)
CAS:896106-16-4
Purity:>98% Package:485RMB/100mg
|
| Company Name: |
Pharmacodia (Beijing) Co.,Ltd
|
| Tel: |
+86-400-851-9921 |
| Email: |
sales@pharmacodia.com |
| Products Intro: |
Product Name:Imiquimod maleate
CAS:896106-16-4
Purity:98% HPLC Package:5mg,10mg,50mg,100mg
|
| Company Name: |
Shanghai YuanYe Biotechnology Co., Ltd.
|
| Tel: |
021-61312847; 18021002903 |
| Email: |
3008007409@qq.com |
| Products Intro: |
Product Name:Imiquimod (maleate)
CAS:896106-16-4
Purity:98% Package:100mg Remarks:T14829
|
IMiquiMod (Maleate) manufacturers
- Imiquimod maleate
-
- $29.00 / 25mg
-
2024-11-19
- CAS:896106-16-4
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | IMiquiMod (Maleate) Basic information |
| | IMiquiMod (Maleate) Chemical Properties |
| storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | form | Powder | | color | White to off-white |
| | IMiquiMod (Maleate) Usage And Synthesis |
| Uses | Imiquimod maleate (R 837 maleate), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod maleate exhibits antiviral and antitumor effects in vivo. Imiquimod maleate can be used for the research of external genital, perianal warts, cancer and COVID-19[1][2]. | | in vivo | In animal models, imiquimod stimulates the innate immune response by increasing NK cell activity, activating macrophages to secrete
cytokines and nitric oxide, and inducing proliferation and differentiation of B lymphocytes. Imiquimod stimulates the innate immune response through induction, synthesis, and release of cytokines, including interferon-a (IFN-α), interleukin (IL)-6, and tumour necrosis factor (TNF)-α[1]. | | IC 50 | TLR7; HSV-1 | | References | [1] Athina Angelopoulou, et al. Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19. Environ Res. 2020 Sep; 188: 109858. DOI:10.1016/j.envres.2020.109858
[2] Aditya K Gupta, et al. Imiquimod: a review. J Cutan Med Surg. Nov-Dec 2002;6(6):554-60. DOI:10.1007/s10227-001-0134-6
[3] Yuji Kan, et al. Imiquimod suppresses propagation of herpes simplex virus 1 by upregulation of cystatin A via the adenosine receptor A1 pathway. J Virol. 2012 Oct;86(19):10338-46. DOI:10.1128/JVI.01196-12
[4] Michael P Sch?n, et al. The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion. J Invest Dermatol. 2006 Jun;126(6):1338-47. DOI:10.1038/sj.jid.5700286 |
| | IMiquiMod (Maleate) Preparation Products And Raw materials |
|